Highest-materiality recent filing
Rigel closes VEPPANU license with Arvinas/Pfizer; pays $70M upfront
Rigel gains exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant).
Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones
Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.
Rigel Q1 revenue up 26% to $58.8M, net income $8.7M; reaffirms FY2026 guidance
Q1 total revenues $58.8M (net product sales $54.9M, contract $3.9M), up 26% YoY.
Lilly terminates ocadusertib license deal with Rigel; effective June 15, 2026
Lilly elected to terminate the License and Collaboration Agreement for ocadusertib on April 16, 2026; effective June 15, 2026.
Rigel Q4 net product sales $65.4M record; full year net income $367M, includes $245.9M tax benefit
Q4 2025 net product sales $65.4M (+41% YoY); TAVALISSE $45.6M (+47%), GAVRETO $10.2M (+27%), REZLIDHIA $9.6M (+29%).
Rigel Pharmaceuticals Provides Preliminary Q4 2025 Revenue of $69.8M and 2026 Outlook of $275-290M
Preliminary Q4 2025 total revenue $69.8M, net product sales $65.4M, vs $57.6M and $46.5M in Q4 2024.
Rigel reports R289 Phase 1b data: 33% RBC-TI in evaluable lower-risk MDS patients
33 patients enrolled (median age 75, median 3 prior therapies); 61% high transfusion burden at baseline.
Rigel Q3 net income $27.9M, raises 2025 revenue guidance to $285-290M
Q3 net income $27.9M ($1.46 diluted EPS) vs $12.4M ($0.70) in Q3 2024.
Rigel Q2 net income $59.6M, revenue $101.7M; raises FY2025 guidance to $270-280M
Q2 2025 total revenue $101.7M (net product sales $58.9M, up 76% YoY); net income $59.6M vs loss $1.0M in Q2 2024.
Rigel Q1 net income $11.4M vs loss; revenue $53.3M (+68% YoY); 2025 outlook reaffirmed
Net product sales $43.6M up 68% YoY: TAVALISSE $28.5M (+35%), GAVRETO $9.0M, REZLIDHIA $6.1M (+25%).
Rigel settles TAVALISSE patent litigation with Annora; generic entry in Q2 2032
Entered settlement with Annora Pharma, Hetero Labs, and Hetero USA resolving patent litigation on TAVALISSE (fostamatinib).
Rigel reports 2024 net income $17.5M, record product sales $144.9M, guides FY25 rev $200-210M
4Q total revenue $57.6M; TAVALISSE $31.0M (+21% YoY), REZLIDHIA $7.4M (+92% YoY), GAVRETO $8.1M.
Rigel reports prelim Q4 total revenue $57.6M, guides FY2025 rev $200-210M
Q4 2024 total revenue $57.6M vs $35.8M Q4 2023; net product sales $46.5M.
22 LR-MDS patients enrolled; median age 76, median 3 prior therapies; 73% high transfusion burden.
Rigel Q3 net income $12.4M vs year-ago loss; revenue $55.3M, led by TAVALISSE +8%
Total Q3 revenue $55.3M; net income $12.4M ($0.71 basic EPS) vs net loss $5.7M in Q3 2023.
Rigel receives $10M upfront; eligible for up to $152.5M in development, regulatory, and commercial milestones.
Rigel Q2 revenue $36.8M, net loss narrows to $1.0M; GAVRETO launch adds $1.9M
Total Q2 revenue $36.8M; TAVALISSE $26.4M (+24% YoY), REZLIDHIA $5.2M (+102% YoY), GAVRETO $1.9M (launched June 27).
Rigel Pharmaceuticals effects 1-for-10 reverse stock split effective June 27, 2024
Board approved 1-for-10 reverse split on June 15; effective June 27 at 12:01 a.m. ET.
Rigel Pharmaceuticals announces 1-for-10 reverse stock split effective June 27, 2024
Reverse stock split at 1-for-10 ratio, reducing shares from ~175.6M to ~17.6M.
Rigel shareholders approve reverse stock split (1:2–1:20) and 6.5M share increase for equity plan
Reverse stock split of common stock at ratio between 1:2 and 1:20 approved; 87.85M for, 42.50M against.
Rigel Q1 2024 revenue $29.5M, net loss $8.2M; acquires GAVRETO, appoints CMO
TAVALISSE net sales $21.1M (down from $22.3M) but bottles shipped hit highest quarterly level since launch.
Rigel Q4 net income $0.7M; TAVALISSE sales $25.7M (+17% YoY); acquires GAVRETO rights
Q4 total revenue $35.8M, TAVALISSE net sales $25.7M (+17% YoY), REZLIDHIA net sales $3.9M (+333% YoY).
Rigel acquires U.S. rights to Blueprint's pralsetinib for $15M plus milestones
Purchase price $15M: $10M at first commercial sale, $5M one year after closing.
Rigel prelim Q4 2023 total revenue ~$35.7M; TAVALISSE record $25.7M; MD Anderson deal $15M
Prelim Q4 total revenue ~$35.7M: TAVALISSE net sales $25.7M (record), REZLIDHIA $3.9M.
Rigel Pharma gets Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq deficiency letter on Nov 27, 2023 for bid price below $1.00 for 30 consecutive business days.
Rigel Q3 2023: Total revenue $28.1M, net loss narrows to $5.7M; TAVALISSE sales record $24.5M
Q3 net loss $5.7M ($0.03/share) vs $19.0M ($0.11/share) in Q3 2022.
Rigel Q2 net loss narrows to $6.6M; TAVALISSE sales up 15% YoY to $21.3M
Q2 net loss $6.6M ($0.04/sh) vs $13.5M loss in Q2 2022; total revenue $26.9M.
Rigel Pharma Q1 net loss narrows to $13.5M; TAVALISSE sales up 38% to $22.3M
Net loss of $13.5M ($0.08/sh) improved from $27.4M ($0.16) in Q1 2022.
Q4 total revenue $51.3M ($21.9M TAVALISSE + $0.9M REZLIDHIA); net income $1.4M ($0.01/share) vs net loss $22.6M in Q4'21.
Rigel Pharmaceuticals CMO Wolfgang Dummer resigns, effective March 31, 2023
Wolfgang Dummer, EVP and Chief Medical Officer, will resign effective March 31, 2023.
Rigel reports preliminary Q4 revenue ~$51.3M; launches REZLIDHIA for AML
Preliminary Q4 total revenue ~$51.3M including TAVALISSE $21.9M (+24% YoY) and REZLIDHIA $0.9M (launched Dec 22).
FDA approves Rigel's REZLIDHIA for mIDH1 relapsed/refractory AML
FDA approved REZLIDHIA (olutasidenib) for adult patients with relapsed/refractory AML with IDH1 mutation.
Rigel Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Rigel on Nov 22, 2022 that its common stock bid price closed below $1.00 for 30 consecutive business days.
Rigel Q3 2022 net loss $19.0M, TAVALISSE sales up 20%, workforce cut 16%
Q3 net loss $19.0M ($0.11/sh) vs $21.0M loss a year ago; total revenue $22.4M.
Rigel's fostamatinib misses primary endpoint in Phase 3 COVID-19 trial; p=0.0603
FOCUS Phase 3 trial of fostamatinib in high-risk hospitalized COVID-19 patients did not meet primary endpoint for days on oxygen (p=0.0603).
Rigel drops wAIHA sNDA after FDA feedback; cuts 16% workforce, 30 jobs
FDA guidance on FORWARD Phase 3 re-analysis leads Rigel to halt sNDA for fostamatinib in wAIHA.
Rigel Q2 TAVALISSE net product sales $18.6M; licenses olutasidenib from Forma; draws $10M term loan
TAVALISSE net product sales of $18.6M, up 9% YoY; total revenues $29.8M; net loss $13.5M ($0.08/share).
Rigel files patent lawsuit against Annora to block generic TAVALISSE
Filed suit in U.S. District Court for New Jersey against Annora Pharma, Hetero Labs, and Hetero USA for patent infringement.
Rigel receives Paragraph IV notice from Annora for generic TAVALISSE; intends to defend patents
Annora Pharma filed ANDA with FDA for generic fostamatinib tablets (100mg and 150mg base).
Primary endpoint of durable hemoglobin response not met: fostamatinib 35.6% vs placebo 26.7% (p=0.398).
Rigel Q1 net loss $27.4M vs prior-year net income; TAVALISSE sales up 31%
Net loss of $27.4M ($0.16/sh) vs net income of $39.5M ($0.23/sh) in Q1 2021.
In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.
On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.
Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.
On March 6, 2025 (the “Effective Date”), Mark J. Frohlich was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc.
On September 16, 2024, Dr. Brian Kotzin notified Rigel Pharmaceuticals, Inc. (“ Rigel ”) of his decision to resign as a member of the Board of Directors of Rigel (the “ Board ”) and from the committees on which he serves, effective September 16, 2024.
Wolfgang Dummer, M.D., Ph.D. informed Rigel Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his position as the Company’s Executive Vice President and Chief Medical Officer.
On October 11, 2022, Dolly A. Vance provided notice of her retirement from her position as general counsel, executive vice president, corporate affairs, and corporate secretary of Rigel, effective the date of this current report.
On the Effective Date, the Board appointed, upon the recommendation of the Board’s Corporate Governance, Health Care Compliance Oversight and Nominating Committee, Kamil Ali-Jackson to fill in the vacancy on the Board and to serve as a member of the Board until her successor is elected and has qualified, or sooner in the event of her death, resignation or removal.
Max materiality 0.90 · Median 0.70 · Most common event other_material